IP Ownership Risk Grows In Booming Cancer Drug Market
By Ryan Hagglund, Lewis Ho and Bonnie Lau · November 20, 2025, 1:55 PM EST
The antibody-drug conjugate, or ADC, space is experiencing an unprecedented surge in dealmaking, establishing itself as one of the most dynamic and high-value domains within biopharma....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login